Amy Olofson

Amy Olofson

Auto-generated profile, based on publicly available information

Amy Olofson

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Journal of Hepatology
Verified
Journal Article
Open access
NFNúria Fabrellas
Núria Fabrellas
PKPatrizia Künzler-Heule
Patrizia Künzler-Heule
AOAmy Olofson
Amy Olofson
KJKathryn Jack
Kathryn Jack
MCMarta Carol
Marta Carol
Cirrhosis represents a major cause of morbidity and mortality, leading to a marked impairment in the quality of life of patients and their caregivers, and resulting in a major burden on healthcare systems. Currently, in most countries, nurses still play a limited role in the care of patients with cirrhosis, which is mainly restricted to the care of patients hospitalised for acute complications of the disease. The current manuscript reviews the established and potential new and innovative roles that nurses can play in the care of patients with cirrhosis. In the hospital setting, specialised nurses should become an integral part of interprofessional teams, helping to improve the quality of care and outcomes of patients with cirrhosis. In the primary care setting, nurses should play an important role in the care of patients with compensated cirrhosis and also facilitate early diagnosis of cirrhosis in those at risk of liver diseases. This review calls for an improved global liver disease education programme for nurses and increased awareness among all healthcare providers and policymakers of the positive impacts of advanced or specialist nursing practice in this domain.

22 May 2024 in Liver Transplantation
Verified
Journal Article
Open access
KRK. Rajender Reddy
K. Rajender Reddy
EWEthan M. Weinberg
Ethan M. Weinberg
SGStevan A. Gonzalez
Stevan A. Gonzalez
MIManhal J. Izzy
Manhal J. Izzy
DSDouglas A. Simonetto
Douglas A. Simonetto
KJKhurram Jamil
Khurram Jamil
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model for End-Stage Liver Disease (MELD) ≥35 were exclusions. Fifty hospitalized patients who received midodrine and octreotide or norepinephrine for HRS-AKI served as a historical comparator cohort. Complete response (CR) was defined as a ≥30% decrease in SCr with end-of-treatment (EOT) SCr≤1.5, partial response as a ≥30% decrease in SCr with EOT SCr>1.5, and nonresponse as a <30% decrease in SCr. CR rate was significantly higher in the terlipressin cohort compared to the historical cohort (64% vs. 16%, p<0.001). Survival, while numerically higher in those who received terlipressin, was statistically similar (D30: 94% vs. 82%, p=0.12; D90: 78% vs. 68%, p=0.37). Renal replacement therapy (RRT) was more common among terlipressin NR than CR and PR (70% vs. 3% vs. 13%, p < 0.001). EOT MELD and SCr were significantly lower within terlipressin cohort (MELD: 19 vs. 25, SCr: 1.4 vs. 2.1 mg/dL, p<0.001). Sixteen of 40 terlipressin-treated patients received LT-alone (terlipressin CR in 10/16). One patient on terlipressin had a hypoxic respiratory failure that responded to diuretics; one possibly had drug-related rash. With continuous terlipressin infusion, a CR rate of 64% was observed with a favorable safety profile. Terlipressin use was associated with lower EOT MELD and SCr than the historical midodrine and octreotide/norepinephrine cohort; LT-alone was accomplished in a high proportion of complete terlipressin responders.

9 April 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CAChathur Acharya
Chathur Acharya
TSTejasav S Sehrawat
Tejasav S Sehrawat
DMDeborah B McGuire
Deborah B McGuire
JSJawaid Shaw
Jawaid Shaw
AFAndrew Fagan
Andrew Fagan
JBJasmohan Bajaj
Jasmohan Bajaj
Background: Health information technology (IT) interventions to decrease readmissions for cirrhosis may be limited by patient-associated factors. Objective: The aim of this study was to determine perspectives regarding adoption versus refusal of health IT interventions among patient-caregiver dyads. Methods: Inpatients with cirrhosis and their caregivers were approached to participate in a randomized health IT intervention trial requiring daily contact with research teams via the Patient Buddy app. This app focuses on ascites, medications, and hepatic encephalopathy over 30 days. Regression analyses for characteristics associated with acceptance were performed. For those who declined, a semistructured interview was performed with themes focused on caregivers, protocol, transport/logistics, technology demands, and privacy. Results: A total of 349 patient-caregiver dyads were approached (191 from Virginia Commonwealth University, 56 from Richmond Veterans Affairs Medical Center, and 102 from Mayo Clinic), 87 of which (25%) agreed to participate. On regression, dyads agreeing included a male patient (odds ratio [OR] 2.08, P=.01), gastrointestinal bleeding (OR 2.3, P=.006), or hepatic encephalopathy admission (OR 2.0, P=.01), whereas opioid use (OR 0.46, P=.03) and alcohol-related etiology (OR 0.54, P=.02) were associated with refusal. Race, study site, and other admission reasons did not contribute to refusing participation. Among the 262 dyads who declined randomization, caregiver reluctance (43%), perceived burden (31%), technology-related issues (14%), transportation/logistics (10%), and others (4%), but not privacy, were highlighted as major concerns. Conclusions: Patients with cirrhosis admitted with hepatic encephalopathy and gastrointestinal bleeding without opioid use or alcohol-related etiologies were more likely to participate in a health IT intervention focused on preventing readmissions. Caregiver and study burden but not privacy were major reasons to decline participation. Reducing perceived patient-caregiver burden and improving communication may improve participation. Trial Registration: ClinicalTrials.gov NCT03564626; https://www.clinicaltrials.gov/ct2/show/NCT03564626

16 May 2025 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
AOAmy Olofson
Amy Olofson
RLRyan Lennon
Ryan Lennon
BKBlake Kassmeyer
Blake Kassmeyer
KLKan Liu
Kan Liu
ZAZacchi I. Attia
Zacchi I. Attia
DSDouglas A. Simonetto
Douglas A. Simonetto
Cirrhosis is a leading cause of morbidity and mortality worldwide, yet preventable at early stages. Currently, effective approaches for early diagnosis are lacking. A novel electrocardiogram (ECG)-enabled deep learning model trained for detection of advanced chronic liver disease (CLD) has demonstrated promising results and it may be used for screening of advanced CLD in primary care. A pragmatic, cluster randomized trial ( NCT05782283 ) in 45 Mayo Clinic primary care practices will be conducted over a period of 6 months with 6 months of follow up. Care teams will be randomized 1:1 to intervention or usual care, stratified by region and patient volume. Patients from providers enrolled in the trial who undergo an ECG during the study period will be included. In the intervention arm, consenting providers to patients identified as higher risk of advanced CLD based on their ECG will be notified with a recommendation for noninvasive fibrosis assessment. The primary endpoint will be detection of advanced CLD (defined as stage 3–4 on blood- or imaging-based noninvasive liver disease assessment or liver biopsy). Secondary outcomes will include completion of fibrosis assessment tests within 180 days of ECG, new diagnosis of liver disease stratified by etiology and risk factors for CLD, and detection of any liver fibrosis (stages 1–4). Post-study surveys to participating clinicians will be conducted. Preliminary findings suggest outstanding potential for the use of an ECG-enabled machine learning algorithm for detection of advanced CLD in the primary care community.

28 September 2020 in JMIR Preprints
Verified
Preprint
Open access
CAChathur Acharya
Chathur Acharya
TSTejasav S Sehrawat
Tejasav S Sehrawat
DMDeborah B McGuire
Deborah B McGuire
JSJawaid Shaw
Jawaid Shaw
AFAndrew Fagan
Andrew Fagan
JBJasmohan Bajaj
Jasmohan Bajaj
BACKGROUND Health information technology (IT) interventions to decrease readmissions for cirrhosis may be limited by patient-associated factors. OBJECTIVE The aim of this study was to determine perspectives regarding adoption versus refusal of health IT interventions among patient-caregiver dyads. METHODS Inpatients with cirrhosis and their caregivers were approached to participate in a randomized health IT intervention trial requiring daily contact with research teams via the Patient Buddy app. This app focuses on ascites, medications, and hepatic encephalopathy over 30 days. Regression analyses for characteristics associated with acceptance were performed. For those who declined, a semistructured interview was performed with themes focused on caregivers, protocol, transport/logistics, technology demands, and privacy. RESULTS A total of 349 patient-caregiver dyads were approached (191 from Virginia Commonwealth University, 56 from Richmond Veterans Affairs Medical Center, and 102 from Mayo Clinic), 87 of which (25%) agreed to participate. On regression, dyads agreeing included a male patient (odds ratio [OR] 2.08, P=.01), gastrointestinal bleeding (OR 2.3, P=.006), or hepatic encephalopathy admission (OR 2.0, P=.01), whereas opioid use (OR 0.46, P=.03) and alcohol-related etiology (OR 0.54, P=.02) were associated with refusal. Race, study site, and other admission reasons did not contribute to refusing participation. Among the 262 dyads who declined randomization, caregiver reluctance (43%), perceived burden (31%), technology-related issues (14%), transportation/logistics (10%), and others (4%), but not privacy, were highlighted as major concerns. CONCLUSIONS Patients with cirrhosis admitted with hepatic encephalopathy and gastrointestinal bleeding without opioid use or alcohol-related etiologies were more likely to participate in a health IT intervention focused on preventing readmissions. Caregiver and study burden but not privacy were major reasons to decline participation. Reducing perceived patient-caregiver burden and improving communication may improve participation. CLINICALTRIAL ClinicalTrials.gov NCT03564626; https://www.clinicaltrials.gov/ct2/show/NCT03564626